Skip to main content

Advertisement

SpringerLink
Log in

Cetuximab zur Radiochemotherapie von Analkarzinomen bei immunkompetenten Patienten ändert bisherigen Therapiestandard nicht

Ergebnisse der prospektiven, multizentrischen E3205-Studie

Cetuximab plus chemoradiotherapy for anal carcinoma in immunocompetent patients does not change existing therapy standards

Results from the prospective, multicenter E3205 trial

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. James RD, Glynne-Jones R, Meadows HM et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 14:516–524

    Article  CAS  PubMed  Google Scholar 

  2. Garg MK, Zhao F, Sparano JA et al (2017) Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol 35:718–726

    Article  PubMed  Google Scholar 

  3. Gunderson LL, Winter KA, Ajani JA et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–4351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Glynne-Jones R, Sebag-Montefiore D, Meadows HM et al (2017) ACT II study group. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. doi:10.1016/s1470-2045(17)30071-2

  5. Doll CM, Moughan J, Klimowicz A et al (2017) Significance of co-expression of epidermal growth factor receptor and Ki67 on clinical outcome in patients with anal cancer treated with chemoradiotherapy: an analysis of NRG Oncology RTOG 9811. Int J Radiat Oncol Biol Phys 97:554–562

    Article  CAS  PubMed  Google Scholar 

  6. Yates A, Carroll S, Kneebone A et al (2015) Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. Clin Oncol (R Coll Radiol) 27:700–707

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Oncology and Palliative Medicine, Nordland Hospital Trust, Prinsensgate 164, P.O. Box 1480, 8092, Bodø, Norwegen

    Carsten Nieder

Authors
  1. Carsten Nieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Nieder.

Ethics declarations

Interessenkonflikt

C. Nieder gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation Garg MK, Zhao F, Sparano JA et al (2017) Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol 35:718–726

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nieder, C. Cetuximab zur Radiochemotherapie von Analkarzinomen bei immunkompetenten Patienten ändert bisherigen Therapiestandard nicht. Strahlenther Onkol 193, 508–509 (2017). https://doi.org/10.1007/s00066-017-1133-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-017-1133-x

Search

Navigation